Systems Biology: A new hope for drug discovery?

Expert Opinion on Drug Discovery

Volumn 1, Issue 7, 2006, Pages 653-661

  Henney, Adriano M ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

biosimulation; computational biology; modelling; systems biology

Indexed keywords

EID: 42249093117     PISSN: 17460441     EISSN: 1746045X     Source Type: Journal    
DOI: 10.1517/17460441.1.7.653     Document Type: Review

References (60)

1. NO AUTHORS LISTED: Pharmaceutical Benchmarking Forum General Metrics Study 1-04, KMR Group, Inc., Chicago, USA.
2. NO AUTHORS LISTED: Innovation or stagnation? Critical path report, March 2004, US Food and Drug Administration (2004):3.
3. NO AUTHORS LISTED: The CMR International 2004 R&D Factbook. Centre for Medicines Research Ltd., Epsom UK (2004).
4. HODGKIN AL, HUXLEY AF: A quantitative description of membrane current and its application to conduction and excitation in nerve. J. Physiol. (1952) 117:500-544.
5. NOBLE D: The music of life: biology beyond the genome. Oxford University Press. Oxford, UK (2006).
6. LAUFFENBURGER DA, FORSTEN KE, WILL B, WILEY HS: Molecular/cell engineering approach to autocrine ligand control of cell function. Ann. Biomed. Eng. (1995) 23:208-215.
7. ARKIN A, ROSS J, MCADAMS HH: Stochastic kinetic analysis of developmental pathway bifurcation in phage lambda-infected Escherichia coli cells. Genetics (1998) 149:1633-1648.
8. MCCULLOCH A, BASSINGTHWAIGHTE J, HUNTER P, NOBLE D: Computational biology of the heart: from structure to function. Prog. Biophys. Mol. Biol. (1998) 69:153-155.
9. WESTERHOFF HV: Subtlety in control - metabolic pathway engineering. Trends Biotechnol. (1995) 13:242-244.
10. TOMITA M, HASHIMOTO K, TAKAHASHI K et al.: E-CELL: software environment for whole-cell simulation. Bioinformatics (1999) 15:72-84.
11. KITANO H: Systems Biology: a brief overview. Science (2002) 295:1662-1665.
12. NOBLE D: The rise of computational biology. Nat. Rev. Mol. Cell Biol. (2002) 3:461-463.
13. NOBLE D: Modelling the heart- from genes to cells to the whole organ. Science (2002) 295:1678-1682.
14. HOOD L, HEATH JR, PHELPS ME, LIN B: Systems biology and new technologies enable predictive and preventative medicine. Science (2004) 306:640-643.
15. WESTERHOFF HV, PALSSON B: The evolution of molecular biology into systems biology. Nat. Biotechnol. (2004) 10:1249-1252.
16. IDEKER T: Systems Biology 101- what you need to know. Nat. Biotechnol. (2004) 22:473-475.
17. ADEREM A: Systems Biology: its practice and challenges. Cell (2005) 121:511-513.
18. SORGER P: A reductionists systems biology. Curr. Opin. Cell Biol. (2005) 17:9-11.
19. WILEY HS: Systems Biology: beyond the buzz. The Scientist (2006):53-57.
20. CASSMAN M, ARKIN A, DOYLE F, KATAGIRI F, LAUFFENBURGER D, STOKES C: International Research and Development in Systems Biology. World Technology Evaluation Centre: Baltimore, USA (2005).
21. HALSEY W: The future of systems biology: emerging technologies and their impact on drug discovery, development and diagnostics. Business Insights Report. Business Insights Ltd (2005).
22. BANGS A, PATERSON T: Finding value in in silico biology. BioSilico (2003) 1(1):18-22.
23. UEHLING M: I, virtual patient. BioIT World, 18 August (2004):50.
24. VAN DER GRIEF J, McBURNEY RN: Rescuing drug discovery: in vivo systems pathology and systems pharmacology. Nat. Rev Drug Discov. (2005) 4:961-967.
25. MCGEE P: Modelling success with in silico tools. Drug Discov. Dev. (2005) 8:24-28.
26. NO AUTHORS LISTED: Models that take drugs. The Economist, 11 June (2005).
27. ASKENOV SV, CHURCH B, DHIMAN A, GEORGIEVA A et al.: An integrated approach for inference and mechanistic modelling for advanced drug development. FEBS Lett. (2005) 579:1878-1883.
28. TRIMMER J, McKENNA C, SUDBECK B, HO R: Use of systems biology in clinical development: design and prediction of a Type 2 diabetes clinical study. In: PAREXELs Pharmaceutical R&D Sourcebook 2004/2005 (Waltham, MA: PAREXEL Internatl Corp., 2004):131.
29. BANGS A: Predictive biosimulation and virtual patients in pharmaceutical R&D. Studies in Health Technology and Informatics (2005) 111:37-42.
30. KANSAL AR, TRIMMER J: Application of predictive biosimulation within pharmaceutical clinical development: examples of significance for translational medicine and clinical trial design. IEE Proc. Syst. Biol. (2005) 152:214-220.
31. CALVANO SE, XIAO W, RICHARDS DR et al.: A network-based analysis of systemic inflammation in humans. Nature (2005) 437:1032-1037.
32. BUGRIM A, KILOLSKAYA T, KIKOLSKY Y: Early prediction of drug metabolism and toxicity: systems biology approach and modelling. Drug Discov. Today (2004) 9:127-135.
33. LYNCH TJ, BELL, DW, SORDELLA R et al.: Specific activating mutations in the epidermal growth factor receptor and responsiveness of non-small cell lung cancer to gefitinib. N. Engl. J. Med. (2004) 350:2129-2139.
34. PAEZ J, JANNE PA, LEE JC et al.: Mutation of the EGFR tyrosine kinase in human non-small cell lung carcinoma. Science (2004) 304:1497-1500.
35. HENDRIKS BS, COOK J, BURKE JM, BEUSMANS JM, LAUFFENBURGER DM, DE GRAAF D. Computational modelling of ErbB family phosphorylation dynamics in response to transforming growth factor alpha and heregulin indicates spatial compartmentation of phosphatase activity. IEE Proc. Syst. Biol. (2006) 153:22-33.
36. HENDRIKS B, GRIFFITHS, GJ, BENSON R et al.: Decreased Internalization of erbb1 mutants in lung cancer is linked with a mechanism conferring sensitivity to gefitinib. IEE Proc. Syst. Biol. (2006) 153: 457-466.
37. HOOD L, PERLMUTTER RM: The impact of systems approaches on biological problems in drug discovery. Nat. Biotechnol. (2004) 22:1215-1217.
38. EUROPEAN SCIENCE FOUNDATION: Systems Biology: a grand challenge for Europe. European Science Foundation Policy briefing. 25 October (2005).
39. ASSOCIATION OF THE BRITISH PHARMACEUTICAL INDUSTRY: Sustaining the skills pipeline in the pharmaceutical and biopharmaceutical industries. ABPI Report, November (2005).
40. http://www.entelos.com/news/newsletters/M AY-NL.pdf Entelos newsletters.
41. http://www.altfutures.com Institute for Alternative Futures, The 2029 Project: Achieving an Ethical Future in Biomedical R&D. Alexandria, Virginia, 2005, the Institute for Alternative Futures.
42. http://www.entelos.com Entelos.
43. http://www.genenetworksciences.com Gene Network Sciences.
44. http://www.bg-medicine.com BG Medicine.
45. http://www.ingenuity.com Ingenuity.
46. http://www.genedata.com Genedata.
47. http://www.genego.com Genego.
48. http://www.genstruct.com Genstruct.
49. http://www.ieedl.org/IP-SYB IET digital library.
50. http://www.nature.com/msb Nature Publishing Group.
51. http://www.bbsrc.ac.uk Biotechnology and Biological Sciences Research Council.
52. http://www.epsrc.ac.uk Engineering and Physical Sciences Research Council.
53. http://www.mib.umist.ac.uk University of Manchester Interdisciplinary Biocentre.
54. http://www.mcisb.org Manchester Centre for Integrative Systems Biology.
55. http://www.csbe.bio.ed.ac.uk Centre for Systems Biology, Edinburgh
56. http://csbi.mit.edu Computational and Systems Biology at MIT.
57. http://www.genomics.princeton.edu Princeton University. Lewis-Sigler Institute for Integrative Genomics.
58. http://www.systemsbiology.org Systems Biology.
59. http://www.sysbio.med.harvard.edu Harvard Medical School, Department of Systems Biology.
60. http://www.systemsx.ch SystemsX. The Swiss Initiative in Systems Biology.